Published in Clin Gastroenterol Hepatol on March 15, 2012
Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol (2013) 1.29
Association of Barrett's esophagus with type II Diabetes Mellitus: results from a large population-based case-control study. Clin Gastroenterol Hepatol (2013) 0.95
Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis. Br J Cancer (2014) 0.92
The role of obesity in oesophageal cancer development. Therap Adv Gastroenterol (2014) 0.90
Metabolic syndrome increases risk of Barrett esophagus in the absence of gastroesophageal reflux: an analysis of SEER-Medicare Data. J Clin Gastroenterol (2015) 0.86
A review of the epidemiology of Barrett's oesophagus and oesophageal adenocarcinoma. Best Pract Res Clin Gastroenterol (2014) 0.85
Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol (2014) 0.84
Association between obesity and Barrett's esophagus in a Japanese population: a hospital-based, cross-sectional study. BMC Gastroenterol (2013) 0.82
Management strategies of Barrett's esophagus. World J Gastroenterol (2012) 0.79
Medical Prevention of Barrett's Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins. Dig Dis Sci (2015) 0.79
Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus. Dig Dis Sci (2014) 0.77
Proton Pump Inhibitors: The Culprit for Barrett's Esophagus? Front Oncol (2015) 0.77
Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus. Clin Gastroenterol Hepatol (2014) 0.77
Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol (2016) 0.76
Esophageal COX-2 expression is increased in Barrett's esophagus, obesity, and smoking. Dig Dis Sci (2014) 0.75
The prevalence of Barrett's-esophagus-associated dysplasia in Puerto Rico. P R Health Sci J (2014) 0.75
Pathogenesis and progression of oesophageal adenocarcinoma varies by prior diagnosis of Barrett's oesophagus. Br J Cancer (2016) 0.75
Operable gastro-oesophageal junctional adenocarcinoma: Where to next? World J Gastrointest Oncol (2014) 0.75
Metabolic syndrome in relation to Barrett's esophagus and esophageal adenocarcinoma: Results from a large population-based case-control study in the Clinical Practice Research Datalink. Cancer Epidemiol (2016) 0.75
Aspirin chemoprevention in barrett esophagus: is the risk worth the benefit? Gastroenterol Hepatol (N Y) (2012) 0.75
Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis. Dig Dis Sci (2015) 0.75
Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol (2008) 7.94
Binge drinking among US adults. JAMA (2003) 7.16
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology (2003) 3.90
Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med (2003) 3.30
Cardiovascular risk factors and confounders among nondrinking and moderate-drinking U.S. adults. Am J Prev Med (2005) 2.88
Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res (1999) 2.51
Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol (1999) 2.50
Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology (1999) 2.46
Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol (2004) 2.09
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res (1998) 1.94
Endoscopic evaluation of patients with dyspepsia: results from the national endoscopic data repository. Gastroenterology (2004) 1.88
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology (2000) 1.84
Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol (2007) 1.79
A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol (2005) 1.63
Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 1.54
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology (2010) 1.51
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol (2001) 1.49
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res (2006) 1.32
Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol (2005) 1.28
Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology (2011) 1.25
Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther (1995) 1.02
Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci (2001) 0.96
The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther (2011) 0.95
Effect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev (2006) 0.95
Gastric acid secretion and parietal cell mass: effect of sex hormones. Gastroenterology (1991) 0.90
Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. Carcinogenesis (2005) 0.88
COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer. Curr Pharm Des (2003) 0.86
Barrett's esophagus. Gastroenterologist (1994) 0.84
Secular trends in patients diagnosed with Barrett's esophagus. Dig Dis Sci (2009) 0.79
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol (2013) 7.81
Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases. JPEN J Parenter Enteral Nutr (2013) 2.94
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy. Clin Gastroenterol Hepatol (2008) 2.74
Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut (2012) 2.65
Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr (2011) 2.49
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst (2012) 2.30
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Case Records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea. N Engl J Med (2014) 2.06
Trends in esophageal adenocarcinoma incidence and mortality. Cancer (2012) 2.03
Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol (2009) 1.93
Geographical variation and incidence of inflammatory bowel disease among US women. Gut (2012) 1.85
Measures of obesity and risk of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2015) 1.66
The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology (2012) 1.65
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology (2012) 1.58
Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.57
QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis (2011) 1.55
Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med (2012) 1.52
Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics (2009) 1.48
Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus. Dig Dis Sci (2014) 1.44
Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis. AJR Am J Roentgenol (2008) 1.42
Hormone therapy increases risk of ulcerative colitis but not Crohn's disease. Gastroenterology (2012) 1.27
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer (2008) 1.26
Convergent evolution of novel protein function in shrew and lizard venom. Curr Biol (2009) 1.25
Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts. BMJ (2013) 1.18
Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer (2014) 1.08
Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis (2014) 1.08
Modeling disease severity in multiple sclerosis using electronic health records. PLoS One (2013) 1.06
Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. Am J Gastroenterol (2013) 1.05
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal (2012) 1.05
Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis. Radiology (2008) 1.04
Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.03
Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors. Inflamm Bowel Dis (2014) 1.03
Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer (2010) 1.01
Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointest Endosc (2010) 1.00
State of Adult Trainee Inflammatory Bowel Disease Education in the United States: A National Survey. Inflamm Bowel Dis (2016) 1.00
Garlic, silver bullets, and surveillance upper endoscopy for Barrett's esophagus. Gastroenterology (2013) 0.97
Deleterious effect of cirrhosis on outcomes after motor vehicle crashes using the nationwide inpatient sample. Am J Gastroenterol (2008) 0.96
Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev (2008) 0.95
Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis (2013) 0.93
Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics (2010) 0.93
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis (2010) 0.93
Quality-of-life assessment of fibroid treatment options and outcomes. Radiology (2011) 0.93
Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model. PLoS Med (2013) 0.92
The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev (2011) 0.91
Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis. Liver Transpl (2012) 0.90
A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg (2010) 0.90
Improving the power of genetic association tests with imperfect phenotype derived from electronic medical records. Hum Genet (2014) 0.89
Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology (2014) 0.88
Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis. Dig Dis Sci (2009) 0.87
Early life factors and risk of inflammatory bowel disease in adulthood. Inflamm Bowel Dis (2013) 0.87
Screening and surveillance for Barrett's esophagus: current issues and future directions. Curr Opin Gastroenterol (2012) 0.87
Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma. PLoS One (2010) 0.87
Association between low density lipoprotein and rheumatoid arthritis genetic factors with low density lipoprotein levels in rheumatoid arthritis and non-rheumatoid arthritis controls. Ann Rheum Dis (2013) 0.86
Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. Dig Dis Sci (2011) 0.86
Endogenous levels of circulating androgens and risk of Crohn's disease and ulcerative colitis among women: a nested case-control study from the nurses' health study cohorts. Inflamm Bowel Dis (2015) 0.86
Initial development of the Temporary Utilities Index: a multiattribute system for classifying the functional health impact of diagnostic testing. Qual Life Res (2010) 0.86
Natural history of Crohn's disease following total colectomy and end ileostomy. Inflamm Bowel Dis (2014) 0.85
Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives. Inflamm Bowel Dis (2012) 0.85
Patients with testicular cancer undergoing CT surveillance demonstrate a pitfall of radiation-induced cancer risk estimates: the timing paradox. Radiology (2012) 0.85
Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. Dig Dis Sci (2011) 0.85
Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother (2010) 0.84
Upper endoscopy in patients with acute myocardial infarction and upper gastrointestinal bleeding: results of a decision analysis. Dig Dis Sci (2008) 0.84
Correlation of polyp number and family history of colon cancer with germline MYH mutations. Clin Gastroenterol Hepatol (2005) 0.84
Patient and societal value functions for the testing morbidities index. Med Decis Making (2013) 0.84
Journal club: How radiation exposure histories influence physician imaging decisions: a multicenter radiologist survey study. AJR Am J Roentgenol (2013) 0.83
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis (2014) 0.83
Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis (2009) 0.83
Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys (2007) 0.82
Impact of mode of delivery on outcomes in patients with perianal Crohn's disease. Inflamm Bowel Dis (2014) 0.81
Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. Am J Gastroenterol (2011) 0.81
Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease. Inflamm Bowel Dis (2010) 0.80
Secular trends in patients diagnosed with Barrett's esophagus. Dig Dis Sci (2009) 0.79
Analysis of barriers to and patients' preferences for CT colonography for colorectal cancer screening in a nonadherent urban population. AJR Am J Roentgenol (2010) 0.79
A simulation model of colorectal cancer surveillance and recurrence. BMC Med Inform Decis Mak (2014) 0.79
Natural history of perianal Crohn's disease after fecal diversion. Inflamm Bowel Dis (2014) 0.79
Clostridium difficile Infection and Risk of Colectomy in Patients with Inflammatory Bowel Disease: A Bias-adjusted Meta-analysis. Inflamm Bowel Dis (2017) 0.79
High C-Reactive Protein Is Associated with Poor Sleep Quality Independent of Nocturnal Symptoms in Patients with Inflammatory Bowel Disease. Dig Dis Sci (2015) 0.79
What is the clinical importance of small polyps with regard to colorectal cancer screening? Nat Clin Pract Gastroenterol Hepatol (2006) 0.78
Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer. AJR Am J Roentgenol (2013) 0.78
Durability of infliximab in Crohn's disease: a single-center experience. Inflamm Bowel Dis (2009) 0.78
Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol (2012) 0.78
Responsiveness of the testing morbidities index in colonoscopy. Value Health (2013) 0.77
Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis. Cancer (2015) 0.77
Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila) (2013) 0.77
Missed polyps, missed opportunities. Gastrointest Endosc (2011) 0.77
Dyssynergic defecation: a treatable cause of persistent symptoms when inflammatory bowel disease is in remission. Dig Dis Sci (2013) 0.76
Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening. Pancreas (2016) 0.76
Esophageal capsule endoscopy for Barrett's esophagus screening: a hard pill to swallow? Clin Gastroenterol Hepatol (2007) 0.76
Vitamin D and IBD: more pieces to the puzzle, still no complete picture. Inflamm Bowel Dis (2011) 0.76
Patient preferences for the chemoprevention of colorectal cancer. Dig Dis Sci (2008) 0.75